Chronic lymphocytic leukaemia: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• BTK 26
• CD19 33
• BCL-2 10
• TP53 3
• CD20 10
• CD22 6
• ABL1 2
• PI3K 1
• NOTCH1 0
• CXCR4 0
• STAT3 0
• CD123 1
• CD38 1
• HMGB1 0
• PD-1 0
• PD-L1 0
• EGFR 0
• HDAC 0
• MDM2 0
• PPAR 0
• TIM-3 0
• AKT 0
• ALK 0
• ATM 0
• BCMA 1
• BDNF 0
• BRAF 0
• BRD4 0
• CD30 0
• CD47 0
• CSF1R 1
• CTNNB1 0
• ERK 0
• FAK 0
• FLT3 0
• IDH 0
• IL-23 0
• IL-4 0
• KMT2A 0
• MAPK 0
• MMP-9 0
• NLRP3 0
• NRAS 0
• PCSK9 0
• PRMT5 0
• TLR4 0
• VEGF 0

24 of 611 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Signaling and Powering Anti-cancer Responses in T Cells SPARC

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €2,500,000· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Immuno-Modulatory Platform for Advanced CLL Therapy (IMPACT)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Czechia· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A single-cell-based solution for an early diagnosis of Richter transformation in patients with chronic lymphocytic leukemia (earlyRTdx)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €150,000· until Oct 2027

5 of 11 running projects, newest first. Listed amounts together: €16.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  64Cu-LLP2A for Imaging Hematologic Malignancies

  NCT06636175· Washington University School of Medicine· Updated 16 Oct 2026

  “Loss of further funding”Registry text, quoted unchanged. Source

• Withdrawn

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Suspended

  ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

  NCT06680661· Leland Metheny· Updated 10 Sept 2026

  “insufficient funding”Registry text, quoted unchanged. Source

• Suspended

  Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

  NCT05400122· David Wald· Updated 14 Jul 2026

  “Drugs unavailable”Registry text, quoted unchanged. Source

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Updated 14 Jul 2026

  “This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

  NCT05515406· Ono Pharmaceutical Co., Ltd.· Updated 29 May 2026

  “The study was terminated due to a strategic decision to discontinue development.”Registry text, quoted unchanged. Source

• Terminated

  Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

  NCT01962636· Masonic Cancer Center, University of Minnesota· Updated 20 May 2026

  “No longer a research question to answer.”Registry text, quoted unchanged. Source

• Terminated

  Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

  NCT03246906· Fred Hutchinson Cancer Center· Updated 14 May 2026

  “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”Registry text, quoted unchanged. Source

• Terminated

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Sun Pharma Advanced Research Company Limited· Updated 13 May 2026

  “Closed for administrative, non-safety-related reasons.”Registry text, quoted unchanged. Source

• Suspended

  Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

  NCT06662227· Wondercel Biotech (ShenZhen)· Updated 7 May 2026

  “Because the implementation of the new regulation policy by the Chinese authority”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

  NCT04301076· National Cancer Institute (NCI)· Source

• Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

  NCT01087333· National Cancer Institute (NCI)· Source

• Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

  NCT03701282· National Cancer Institute (NCI)· Source

• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  NCT04269902· National Cancer Institute (NCI)· Source

• A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· BeOne Medicines· Source

• A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

  NCT07709000· Merck Sharp & Dohme LLC· Source

• Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

  NCT06676033· National Heart, Lung, and Blood Institute (NHLBI)· Source

• A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

  NCT06524375· Genentech, Inc.· Source

• A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Janssen Cilag International· Source

• A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  NCT05947851· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 21
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 4
• Machine Learning 10
• Cohort Studies 18
• Genome-Wide Association Study 2

• Scalable Arrayed T-cell CRISPR Screening in Autologous Tumor Co-cultures to Prioritize Combination Partners for T-cell Engagers.

  Curr Protoc, Nov 2026

See which targets of this disease your abstract mentions, and go to the people working on them.